Ipsen targets MEA growth with Dubai base

French biopharmacy company opens facilities in Dubai Healthcare City

START READING

Monday 20 September 2021

French biopharmacy company Ipsen has opened an office at Dubai Healthcare City (DHC) to serve as its new Middle East and Africa (MEA) base.

The company said its office will allow it to kick-start direct operations and bring treatments to serve demand in the fields of oncology, rare diseases, and neuroscience.

With over 90 years of heritage, Ipsen focuses on introducing innovative treatments and breakthrough medicines that help enhance the quality of life. It was founded in 1929 and has grown into a group with net sales of more than EUR 2.5 billion and about 5,700 employees. The company sells 20 medicines and has a direct presence in more than 30 countries, including research facilities in France, the UK, the US, and China. It spends more than 15% of its net sales on research.

The pharmaceutical sector is one of 11 key markets identified by the UAE government as a target for development under the 'Operation 300bn' strategy that seeks to increase the industrial sector's contribution to GDP to AED 300 billion from the current AED 133 billion.